Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Xolair Prior Auth | OpenPa…
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy N/A

    Xolair (omalizumab) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for self-administered subcutaneous Xolair prefilled syringe and prefilled autoinjector formulations. It establishes initial authorization and reauthorization requirements for asthma and chronic urticaria and describes covered indications and limitations of use.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyXolair (omalizumab) Coverage and Prior Authorization
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionDocument that Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
    SourceLink
    POLICY UPDATE CHANGES

    The policy requires that Xolair not be used with specified interleukin-4, interleukin-5, or TSLP therapies for the same indication.

    Exdensur was added to the examples of anti-interleukin-5 inhibitors that must not be used in combination with Xolair.

    The chronic urticaria prerequisite therapy criteria were updated.

    4FDA-indicated conditions described
    12 monthsInitial authorization duration
    30–1300 IU/mL

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Asthma IgE range
    3Restricted combination therapy classes
    >12 weeksNasal-polyp symptom duration
    Epinephrine accessFood allergy requirement

    Coverage Criteria

    Asthma — Initial Authorization

    Xolair is covered for moderate to severe persistent asthma when ALL applicable criteria in at least ONE pathway are met.

    ONE of the following pathways

    • Established therapy pathway

      • Patient has been established on Xolair therapy for moderate to severe persistent asthma under an active medical benefit prior authorization.
      • Documentation of positive clinical response

        • Reduction in the frequency of exacerbations.
        • Decreased utilization of rescue medications.
        • Increase in percent predicted FEV1 from pretreatment baseline.
        • Reduction in severity or frequency of asthma-related symptoms, such as wheezing, shortness of breath, or coughing.
      • Xolair is being used in combination with an ICS-containing maintenance medication, such as Advair/AirDuo, Breo Ellipta, Symbicort, or Trelegy Ellipta.
      • Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or thymic stromal lymphopoietin (TSLP) inhibitor for the same indication.
    • New therapy pathway

      • Diagnosis of moderate to severe asthma.
      • Asthma is uncontrolled or inadequately controlled as demonstrated by at least ONE of the following

        • Poor symptom control, such as an Asthma Control Questionnaire (ACQ) score consistently greater than 1.5 or Asthma Control Test (ACT) score consistently less than 20.
        • Two or more bursts of systemic corticosteroids lasting at least 3 days each in the previous 12 months.
        • Asthma-related emergency treatment, including an emergency room visit, hospital admission, or unscheduled physician office visit for nebulizer or other urgent treatment.
        • Airflow limitation, such as post-bronchodilator FEV1 less than 80% predicted in the face of reduced FEV1/FVC below the lower limit of normal.

    Asthma — Reauthorization

    Xolair reauthorization requires ALL of the following criteria.

    ALL of the following

    • Documentation of positive clinical response

      • Reduction in the frequency of exacerbations.
      • Decreased utilization of rescue medications.
      • Increase in percent predicted FEV1 from pretreatment baseline.
      • Reduction in severity or frequency of asthma-related symptoms, such as wheezing, shortness of breath, or coughing.
    • Xolair is being used in combination with an ICS-containing maintenance medication, such as Advair/AirDuo, Breo Ellipta, Symbicort, or Trelegy Ellipta.

    Chronic Urticaria — Initial Authorization Pathways

    Xolair is covered for chronic urticaria when ALL applicable criteria in at least ONE pathway are met.

    ONE of the following pathways

    • Established therapy pathway

      • Patient has been established on Xolair therapy for chronic urticaria under an active medical benefit prior authorization.
      • Documentation of positive clinical response to Xolair therapy, such as reduction in exacerbations, itch severity, or hives.
      • Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
    • New therapy pathway

      • Diagnosis of chronic urticaria.

    Chronic Urticaria — Initial Therapy Criteria

    For the new-therapy pathway, ALL applicable criteria must be met.

    ALL of the following

    • Diagnosis of chronic urticaria.
    • Patient remains symptomatic despite ONE of the following treatment histories

      • At least a 2-week trial of, or documented contraindication or intolerance to, two H1-antihistamines, such as Allegra, Benadryl, or Claritin.
      • At least a 2-week trial of updosing a second-generation H1-antihistamine up to 4-fold after being unresponsive to at least a 2-week trial of a standard-dose second-generation H1-antihistamine.
      • At least a 2-week trial of, or contraindication or intolerance to, BOTH of the following taken in combination

    Chronic Urticaria — Reauthorization

    Xolair reauthorization requires ALL of the following criteria.

    ALL of the following

    • Documentation of positive clinical response to Xolair therapy, such as reduction in exacerbations, itch severity, or hives.
    • Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.

    Nasal Polyps — Initial Authorization

    Xolair is covered for nasal polyps when ALL applicable criteria in at least ONE pathway are met.

    ONE of the following pathways

    • Established therapy pathway

      • Patient has been established on Xolair therapy for nasal polyps under an active medical benefit prior authorization.
      • Documentation of positive clinical response to Xolair therapy.
      • Patient will continue Xolair as add-on maintenance therapy in combination with intranasal corticosteroids, such as fluticasone, mometasone, or triamcinolone.
      • Patient is not receiving Xolair in combination with an anti-interleukin 5 therapy, anti-interleukin 4 therapy, or TSLP inhibitor for the same indication.
    • New therapy pathway

    Nasal Polyps — Reauthorization / Maintenance Therapy

    Xolair reauthorization and maintenance therapy require ALL of the following criteria.

    ALL of the following

    • Documentation of positive clinical response to Xolair therapy.
    • Patient will continue to receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids, such as fluticasone, mometasone, or triamcinolone.
    • Patient is not receiving Xolair in combination with an anti-interleukin 5 therapy, anti-interleukin 4 therapy, or TSLP inhibitor for the same indication.

    IgE-Mediated Food Allergy — Established Therapy

    Xolair is covered for established IgE-mediated food allergy therapy when ALL criteria are met.

    ALL of the following

    • Established therapy and response

      • Patient has been established on Xolair therapy for IgE-mediated food allergy under an active medical benefit prior authorization.
      • Documentation of positive clinical response to Xolair therapy, such as reduction in type I allergic reactions.
    • Xolair will be used in conjunction with food allergen avoidance.
    • Patient has access to epinephrine.
    • Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.

    IgE-Mediated Food Allergy — New Diagnosis

    Xolair is covered for a new IgE-mediated food allergy diagnosis when ALL criteria are met.

    ALL of the following

    • Diagnosis of IgE-mediated food allergy to one or more foods.
    • Patient is aged >= 1 year.
    • IgE-mediated food allergy to the specific food(s) is confirmed by BOTH of the following

      • History of type I allergic reactions, such as nausea, vomiting, cramping, diarrhea, flushing, pruritus, urticaria, swelling of the lips, face, or throat, wheezing, lightheadedness, or syncope.
      • One of the following confirmatory tests

        • Food-specific skin prick testing (SPT).

    IgE-Mediated Food Allergy — Reauthorization

    Xolair reauthorization requires ALL of the following criteria.

    ALL of the following

    • Documentation of positive clinical response to Xolair therapy, such as reduction in type I allergic reactions.
    • Xolair will be used in conjunction with food allergen avoidance.
    • Patient has access to epinephrine.
    • Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
    • Prescriber is one of the following

      • Allergist.

    Xolair is not indicated for acute bronchospasm or status asthmaticus; emergency treatment of allergic reactions, including anaphylaxis; or other forms of urticaria.

    Xolair must not be used in combination with another biologic for treatment of the same indication, including anti-interleukin 4 therapy, anti-interleukin 5 therapy, or a thymic stromal lymphopoietin (TSLP) inhibitor.

    For IgE-mediated food allergy, Xolair must not be used in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.

    Clinical Thresholds and Documentation Values

    Baseline serum total IgE
    Minimum serum total IgE≥ 30 IU/mL
    Maximum serum total IgE≤ 1300 IU/mL
    Required measurementBaseline pre-omalizumab serum total IgE
    Asthma Control Questionnaire
    Asthma Control Questionnaire thresholdConsistently greater than 1.5
    Clinical useDefines poor symptom control
    Assessment toolAsthma Control Questionnaire (ACQ)

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Xolair Formulation and Administration Scope

    Prior authorization applies to Xolair (omalizumab) prefilled syringe and prefilled autoinjector formulations used for self-administered subcutaneous therapy.

    • Covered formulation scope: prefilled syringe and prefilled autoinjector.
    • Route and use: self-administered subcutaneous injection.
    Prior Authorization

    Initial Asthma Authorization

    For initial asthma authorization, submit documentation showing uncontrolled or inadequately controlled asthma despite intensive controller therapy, qualifying laboratory and allergy testing, and specialist prescribing.

    • Patient is at least 6 years old with moderate-to-severe persistent asthma.
    • Document poor symptom control, at least two systemic corticosteroid bursts of 3 or more days in the prior 12 months, asthma-related emergency treatment, qualifying airflow limitation, or current oral-corticosteroid dependence.
    • Use Xolair with a maximally dosed age-appropriate ICS/LABA combination plus one additional asthma controller medication.

    Policy and Drug Background

    Xolair (omalizumab) is an anti-IgE antibody. The policy describes coverage for moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria. Authorization criteria address clinical qualification, required concomitant therapy where applicable, documentation of response for continuation, and avoidance of specified concurrent biologic therapies.

    Key Definitions

    Uncontrolled or inadequately controlled asthma
    Poor symptom controlAsthma Control Questionnaire score consistently greater than 1.5 or Asthma Control Test score consistently less than 20
    Exacerbation historyTwo or more systemic corticosteroid bursts of at least 3 days each in the previous 12 months
    Emergency treatmentAsthma-related emergency room visit, hospital admission, or unscheduled office visit for nebulizer or other urgent treatment
    Airflow limitationFEV1 less than 80% predicted after appropriate bronchodilator withhold, with reduced FEV1/FVC below the lower limit of normal
    Oral corticosteroid dependenceCurrent dependence on oral corticosteroids for asthma treatment
    Chronic spontaneous urticaria

    Initial Therapy Pathways

    Asthma Initial Therapy

    Asthma initial authorization requires one of two pathways.

    Asthma initial therapy pathways

    • Established Xolair therapy

      • Positive clinical response: Reduction in exacerbations; decreased rescue-medication use; increased percent-predicted FEV1 from pretreatment baseline; or reduced severity or frequency of asthma-related symptoms.
    • New Xolair therapy

      • Uncontrolled or inadequately controlled asthma: Poor symptom control; at least two systemic corticosteroid bursts of at least 3 days each in the previous 12 months; asthma-related emergency treatment; airflow limitation; or current oral-corticosteroid dependence.

    Reauthorization and Continuation

    Asthma Reauthorization

    Asthma reauthorization requires all of the following.

    Asthma continuation: Positive clinical response to Xolair is documented; Xolair remains combined with an ICS-containing maintenance medication; and Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.Authorization duration: 12 months

    Xolair Chronic Urticaria Continuation

    Chronic urticaria continuation requires all of the following.

    Chronic urticaria continuation: Positive clinical response to Xolair is documented, and Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.Authorization duration: 12 months

    Required Prior Treatment

    StepQualifying treatment historyRequirement
    1
    Trial of two H1-antihistamines
    Persistent symptoms despite at least a 2-week trial of two H1-antihistamines; a documented contraindication or intolerance may substitute.
    1
    Updose a second-generation H1-antihistamine
    Persistent symptoms despite at least a 2-week standard-dose trial followed by updosing up to 4-fold.
    1
    Combination antihistamine therapy
    Persistent symptoms despite at least a 2-week trial of a second-generation H1-antihistamine combined with one additional therapy: a different second-generation H1-antihistamine, first-generation H1-antihistamine, H2-antihistamine, or leukotriene modifier; contraindication or intolerance may substitute.
    StepQualifying treatment historyRequirement
    1
    Intranasal corticosteroid plus another nasal-polyp therapy
    Unable to obtain symptom relief after intranasal corticosteroids plus nasal saline irrigation or an antileukotriene agent.
    1
    Systemic corticosteroid use
    Required systemic corticosteroids for nasal polyps within the previous 2 years.
    1
    Prior sinus surgery
    Required prior sinus surgery for nasal polyps.
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyXolair (omalizumab) Coverage and Prior Authorization
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionDocument that Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Documentation ValuesAuthorization, Documentation, and Denial RisksPolicy and Drug BackgroundKey DefinitionsInitial Therapy PathwaysReauthorization and ContinuationRequired Prior Treatment
    Patient is currently dependent on oral corticosteroids for treatment of asthma.
  1. Medical records document a baseline, pre-omalizumab serum total IgE level >= 30 IU/mL and <= 1300 IU/mL.
  2. Positive skin test or in vitro reactivity to a perennial aeroallergen.
  3. Xolair is used in combination with ONE of the following controller regimens

    • One maximally dosed, appropriately age-adjusted combination ICS/long-acting beta2 agonist (LABA), such as Advair/AirDuo Respiclick, Symbicort, or Breo Ellipta.
    • Combination therapy including both of the following

      • One maximally dosed, appropriately age-adjusted ICS product, such as Alvesco, Asmanex, or QVAR.
      • One additional asthma controller medication, such as a LABA, leukotriene receptor antagonist, or theophylline.
  4. Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
  5. Prescriber is one of the following

    • Allergist.
    • Immunologist.
    • Pulmonologist.
  6. Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
  7. Authorization will be issued for 12 months.

    Reauthorization period.

  8. A second-generation H1-antihistamine, such as Allegra, Claritin, or Zyrtec.
  9. One additional therapy

    • A different second-generation H1-antihistamine.
    • A first-generation H1-antihistamine, such as Benadryl, Chlor-Trimeton, or Vistaril.
    • An H2-antihistamine, such as Pepcid, Tagamet HB, or Zantac.
    • A leukotriene modifier, such as Singulair.
  10. Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
  11. Prescriber is one of the following

    • Allergist.
    • Dermatologist.
    • Immunologist.
    • Diagnosis of nasal polyps.
    • At least TWO of the following symptoms for longer than 12 weeks

      • Nasal mucopurulent discharge.
      • Nasal obstruction, blockage, or congestion.
      • Facial pain, pressure, and/or fullness.
      • Reduction or loss of sense of smell.
    • At least ONE objective finding on nasal endoscopy and/or sinus CT

      • Purulent mucus or edema in the middle meatus or ethmoid regions.
      • Polyps in the nasal cavity or middle meatus.
      • Radiographic imaging demonstrating mucosal thickening or partial or complete opacification of the paranasal sinuses.
    • At least ONE of the following treatment histories

      • ALL of the following

        • Patient has been unable to obtain symptom relief after a trial of intranasal corticosteroids, such as fluticasone, mometasone, or triamcinolone.
        • AND one other therapy used in management of nasal polyps

          • Nasal saline irrigations.
          • Antileukotriene agent, such as montelukast, zafirlukast, or zileuton.
      • Patient has required systemic corticosteroids, such as prednisone or methylprednisolone, for nasal polyps in the previous 2 years.
      • Patient has required prior sinus surgery.
    • Patient will receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids, such as fluticasone, mometasone, or triamcinolone.
    • Patient is not receiving Xolair in combination with an anti-interleukin 5 therapy, anti-interleukin 4 therapy, or TSLP inhibitor for the same indication.
    • Prescriber is one of the following

      • Allergist.
      • Immunologist.
      • Otolaryngologist.
      • Pulmonologist.
  12. Prescriber is one of the following

    • Allergist.
    • Immunologist.
  13. IgE antibody in vitro testing.
  14. Oral food challenge (OFC).
  15. Xolair will be used in conjunction with food allergen avoidance.
  16. Patient has access to epinephrine.
  17. Patient is not receiving Xolair in combination with an anti-interleukin 4 therapy, anti-interleukin 5 therapy, or TSLP inhibitor for the same indication.
  18. Prescriber is one of the following

    • Allergist.
    • Immunologist.
  19. Immunologist.
  20. Authorization will be issued for 12 months.

    Reauthorization period.

  21. Asthma Control Test
    Asthma Control Test thresholdConsistently less than 20
    Clinical useDefines poor symptom control
    Assessment toolAsthma Control Test (ACT)
    Airflow limitation thresholds
    FEV1 thresholdLess than 80% predicted
    Bronchodilator conditionMeasured after appropriate bronchodilator withhold
    FEV1/FVC requirementReduced FEV1/FVC below the lower limit of normal
    Systemic corticosteroid bursts
    Number of burstsAt least 2 systemic corticosteroid bursts
    Duration of each burstAt least 3 days each
    Look-back periodPrevious 12 months
    Second-generation H1-antihistamine updosing
    Maximum updosingUp to 4-fold
    Standard-dose trial before updosingAt least 2 weeks
    Updosed-treatment trialAt least 2 weeks
    Nasal-polyp symptom duration
    Minimum symptom durationLonger than 12 weeks
    Number of qualifying symptomsTwo or more
    Examples of qualifying symptomsNasal mucopurulent discharge; nasal obstruction, blockage, or congestion; facial pain, pressure, or fullness; or reduced or lost sense of smell
    Prior systemic corticosteroid use
    Look-back periodPrevious 2 years
    TreatmentSystemic corticosteroids, such as prednisone or methylprednisolone
    Qualifying conditionRequired for nasal polyps when this treatment-history alternative is used
  22. Prescriber must be an allergist, immunologist, or pulmonologist.
  23. Prior Authorization

    Asthma Reauthorization

    Asthma reauthorization requires evidence that Xolair is working and that maintenance controller therapy continues. The patient must not receive another biologic for the same indication.

    • Document at least one response: fewer exacerbations, less rescue-medication use, increased percent-predicted FEV1, or reduced severity/frequency of wheezing, shortness of breath, coughing, or other asthma symptoms.
    • Continue an ICS-containing maintenance medication.
    • Do not combine with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
    Prior Authorization

    Initial Chronic Urticaria Authorization: Established Therapy

    For initial chronic spontaneous urticaria authorization through the established-therapy pathway, document active prior authorization history, clinical response, and the required prescribing and combination-therapy safeguards.

    • Patient must already be established on Xolair for chronic urticaria under an active medical-benefit prior authorization.
    • Document positive clinical response, such as reduced exacerbations, itch severity, or hives.
    • Prescriber must be an allergist, dermatologist, or immunologist.
    • Do not combine with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
    Documentation Required

    Initial Chronic Urticaria Authorization: New Therapy

    For a new chronic urticaria authorization, document the diagnosis and a qualifying history of persistent symptoms despite appropriate H1-antihistamine therapy or documented contraindication/intolerance.

    • Patient must have a diagnosis of chronic urticaria.
    • Submit the applicable antihistamine trial, updosing, combination-therapy, contraindication, or intolerance history.
    • Prescriber must be an allergist, dermatologist, or immunologist.
    • Do not combine with another prohibited biologic for the same indication.
    Prior Authorization

    Initial Nasal-Polyp Authorization

    For initial nasal-polyp authorization, use either the established-therapy pathway or the new-therapy clinical qualification pathway. Both pathways require add-on intranasal corticosteroid therapy and appropriate specialist oversight.

    • Established therapy: document active prior authorization history, positive response, continued intranasal corticosteroid use, and specialist prescribing.
    • New therapy: document nasal-polyps diagnosis, qualifying symptoms lasting more than 12 weeks, objective endoscopy or CT findings, and required prior treatment history.
    • Prescriber must be an allergist, immunologist, otolaryngologist, or pulmonologist.
    • Do not combine with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication.
    Prior Authorization

    Initial Authorization Term

    Initial authorization for Xolair is issued for 12 months when the applicable indication-specific criteria are met.

    • Authorization term: 12 months.
    Prior Authorization

    Established Food Allergy Therapy

    For patients already receiving Xolair for IgE-mediated food allergy, document the existing authorization, positive response, safety measures, avoidance plan, and specialist prescriber.

    • Document established Xolair therapy under an active prior authorization and positive response, such as reduced type I allergic reactions.
    • Xolair must be used with food-allergen avoidance.
    • Patient must have access to epinephrine.
    • Prescriber must be an allergist or immunologist.
    • Do not combine with another prohibited biologic for the same indication.
    Prior Authorization

    Initial Food Allergy Authorization

    For a new food-allergy authorization, submit documentation confirming IgE-mediated allergy and the patient's age, safety plan, avoidance plan, and specialist prescriber.

    • Patient must be at least 1 year old and have IgE-mediated food allergy to one or more foods.
    • Confirm the specific food allergy with both a history of type I allergic reactions and food-specific skin-prick testing, in-vitro IgE testing, or an oral food challenge.
    • Xolair must be used with food-allergen avoidance, and the patient must have access to epinephrine.
    • Prescriber must be an allergist or immunologist.
    Step Therapy

    Chronic Urticaria Antihistamine Step Therapy

    For chronic urticaria, document that symptoms persist despite an adequate H1-antihistamine step-therapy trial or that the required therapies are contraindicated or not tolerated.

    • At least 2 weeks of two H1-antihistamines; or
    • At least 2 weeks of up-dosing a second-generation H1-antihistamine up to fourfold after failure of at least 2 weeks at standard dose; or
    • At least 2 weeks of a second-generation H1-antihistamine combined with a different second-generation H1-antihistamine, first-generation H1-antihistamine, H2-antihistamine, or leukotriene modifier.
    • Document contraindication or intolerance when used instead of a trial.
    Step Therapy

    Nasal-Polyp Treatment History

    For nasal polyps, document prior treatment with intranasal corticosteroids and another accepted management therapy, or qualifying systemic corticosteroid or surgical history.

    • Document inability to obtain symptom relief after intranasal corticosteroids plus nasal saline irrigation or an antileukotriene agent.
    • Alternatively, document systemic corticosteroid use for nasal polyps within the prior 2 years or prior sinus surgery.
    • Continue intranasal corticosteroid therapy as add-on maintenance treatment.

    Unsupported block type: documentation under physician?

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Denial Risk

    Concurrent Biologic Therapy

    Do not submit Xolair concurrently with another biologic for treatment of the same indication.

    • Prohibited combinations include anti-interleukin-4 therapy, such as Dupixent (dupilumab).
    • Prohibited combinations include anti-interleukin-5 therapy, such as Cinqair, Exdensur, Fasenra, or Nucala.
    • Prohibited combinations include the TSLP inhibitor Tezspire (tezepelumab).

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: documentation

    Unsupported block type: prior_auth

    PopulationAdults and adolescents 12 years of age and older
    ConditionChronic urticaria
    Treatment statusRemains symptomatic despite H1-antihistamine treatment
    Type I allergic reaction
    Gastrointestinal symptomsNausea, vomiting, cramping, or diarrhea
    Skin symptomsFlushing, pruritus, or urticaria
    SwellingSwelling of the lips, face, or throat
    Respiratory symptomsWheezing
    Circulatory or neurologic symptomsLightheadedness or syncope
    Food allergy confirmation
    Skin testingFood-specific skin prick testing (SPT)
    Laboratory testingIgE antibody in vitro testing
    Challenge testingOral food challenge (OFC)
    Controller therapy: One maximally dosed, age-appropriate ICS/LABA combination, or a maximally dosed, age-appropriate ICS plus one additional asthma controller medication.

    Chronic Urticaria Initial Therapy

    Chronic urticaria initial therapy requires one of two pathways.

    Chronic urticaria initial therapy pathways

    • Established Xolair therapy

      • Positive clinical response: Reduction in exacerbations, itch severity, or hives.
    • New chronic urticaria therapy

      • Qualifying antihistamine treatment: At least a 2-week trial of two H1-antihistamines; or up to four-fold updosing of a second-generation H1-antihistamine after nonresponse to at least a 2-week standard-dose trial; or at least a 2-week trial of specified combination antihistamine therapy.

    Xolair for Chronic Urticaria

    Xolair initial therapy for chronic urticaria requires all of the following.

    Chronic urticaria qualification

    • Qualifying antihistamine treatment

      • Persistent symptoms despite at least a 2-week trial of, or contraindication or intolerance to, two H1-antihistamines.
      • Persistent symptoms despite at least a 2-week trial of a second-generation H1-antihistamine updosed up to four-fold after nonresponse to at least a 2-week standard-dose trial.Up to 4-fold
      • Persistent symptoms despite at least a 2-week trial of, or contraindication or intolerance to, a second-generation H1-antihistamine combined with a different second-generation H1-antihistamine, first-generation H1-antihistamine, H2-antihistamine, or leukotriene modifier.

    Established Therapy

    The established food allergy therapy pathway requires all of the following.

    Established IgE-mediated food allergy therapy: Established Xolair therapy for IgE-mediated food allergy under an active UnitedHealthcare medical benefit prior authorization; documented positive clinical response; use with food allergen avoidance; access to epinephrine; no prohibited same-indication biologic combination; and prescribing by an allergist or immunologist.Authorization duration: 12 months

    New IgE-Mediated Food Allergy

    The newly evaluated patient pathway requires all of the following.

    New IgE-mediated food allergy: Diagnosis of IgE-mediated food allergy to one or more foods; age at least 1 year; history of type I allergic reactions; confirmation by food-specific skin-prick testing, IgE antibody in-vitro testing, or oral food challenge; food allergen avoidance; epinephrine access; no prohibited same-indication biologic combination; and prescribing by an allergist or immunologist.Age ≥1 year

    Authorization duration: 12 months

    Xolair Nasal-Polyp Continuation

    Nasal-polyp continuation requires all of the following.

    Nasal-polyp continuation: Positive clinical response to Xolair is documented; Xolair continues as add-on maintenance therapy with intranasal corticosteroids; and Xolair is not used with an anti-interleukin-5 therapy, anti-interleukin-4 therapy, or TSLP inhibitor for the same indication.

    Continuation—Maintenance Therapy

    Continuation requires all of the following.

    Continued maintenance therapy: Positive clinical response to Xolair is documented; Xolair continues as add-on maintenance therapy with intranasal corticosteroids; and Xolair is not used with an anti-interleukin-5 therapy, anti-interleukin-4 therapy, or TSLP inhibitor for the same indication.Authorization duration: 12 months

    Continuation—IgE-Mediated Food Allergy

    Food allergy continuation requires all of the following.

    Continued IgE-mediated food allergy therapy: Positive clinical response to Xolair is documented; Xolair is used with food allergen avoidance; the patient has access to epinephrine; Xolair is not used with an anti-interleukin-4 therapy, anti-interleukin-5 therapy, or TSLP inhibitor for the same indication; and the prescriber is an allergist or immunologist.Authorization duration: 12 months